SAN DIEGO, May 19, 2014 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTCBB:INNV) today announced the issuance on May 13, 2014 of its Canadian patent No. 2,417,552 entitled “Compositions and Methods for Treating Sexual Response” (the “‘552 Patent”). The ‘552 Patent is the first patent granted for Zestra® in Canada and is valid until June 2021. The ‘552 is the tenth patent that the Company’s wholly-owned subsidiary, Semprae Laboratories, Inc. has been issued throughout the world.
Help employers find you! Check out all the jobs and post your resume.
